Endometrial cancer is one of the common malignant tumors in women, and its incidence rate has increased significantly in recent years with a trend of rejuvenation. The treatment of endometrial cancer is mainly based on surgery, supplemented by radiotherapy and chemotherapy. Chemotherapy for early stage endometrial cancer Early stage of endometrial cancer refers to stage I (lesions limited to uterine body) and stage II (lesions involving cervix), with 5-year survival rate up to 80-90%, and surgery is preferred for such patients. Postoperative adjuvant chemotherapy should be given to patients with the following high-risk factors: (1) histological grade III (hypofractionated G3); (2) lesions infiltrating >1/2 of the uterine wall; (3) lesions involving >50% of the uterine cavity or involving the lower uterine segment or isthmus; (4) postoperative pathological confirmation of interstitial choroidal involvement; (5) special pathological types, such as plasmacytoid papillary adenocarcinoma, clear cell carcinoma, etc. Chemotherapy can reduce the rate of distant metastasis in patients with early-stage endometrial cancer and reduce the risk of death by 7%. Chemotherapy for advanced and recurrent endometrial cancer The prognosis of advanced and recurrent endometrial cancer is very poor, and the average survival time is only 12 months, chemotherapy is the main treatment method, which can improve the survival rate of patients and can be the first choice.